Sola Caroline, André Pascale, Lemmers Céline, Fuseri Nicolas, Bonnafous Cécile, Bléry Mathieu, Wagtmann Nicolai R, Romagné François, Vivier Eric, Ugolini Sophie
Innate-Pharma, 13009 Marseille, France.
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. doi: 10.1073/pnas.0901653106. Epub 2009 Jun 26.
Natural killer (NK) cells are lymphocytes of the innate immune system able to recognize and kill tumors lacking self-MHC class I molecules. This "missing-self" recognition is mediated by the lack of engagement of MHC class I-specific inhibitory NK cell receptors that include the killer cell Ig-like receptors (KIR) in humans and Ly49 molecules in mice. A promising immunotherapeutic strategy against MHC class I(+) cancer cells is to block NK cell inhibitory receptors using monoclonal antibodies (mAb). However, interactions between MHC class I molecules and their inhibitory receptors are also required for the acquisition of NK cell functional competence, a process referred as to "education." In addition, inhibitory receptors are involved in self-tolerance on educated NK cells. Here, we developed a preclinical mouse model in which all NK cells are educated by a single transgenic inhibitory receptor, human KIR2DL3, through the engagement with its HLA-Cw3 ligand. This approach revealed that NK cells could be reprogrammed to control the development of mouse syngenic tumors in vivo. Moreover, in vivo anti-KIR mAb treatment induced the killing of HLA(+) target cells without breaking self-tolerance. Finally, the long-term infusion of anti-KIR mAb neither abolished NK cell education nor tumor cell recognition. Therefore, these results strongly support the use of inhibitory receptor blockade in cancer patients.
自然杀伤(NK)细胞是先天性免疫系统的淋巴细胞,能够识别并杀死缺乏自身MHC I类分子的肿瘤细胞。这种“缺失自我”识别是由MHC I类特异性抑制性NK细胞受体未被激活介导的,这些受体在人类中包括杀伤细胞免疫球蛋白样受体(KIR),在小鼠中包括Ly49分子。一种针对MHC I(+)癌细胞的有前景的免疫治疗策略是使用单克隆抗体(mAb)阻断NK细胞抑制性受体。然而,MHC I类分子与其抑制性受体之间的相互作用对于NK细胞功能能力的获得也是必需的,这一过程称为“教育”。此外,抑制性受体参与了受过教育的NK细胞的自身耐受性。在这里,我们开发了一种临床前小鼠模型,其中所有NK细胞都通过与人类KIR2DL3的HLA-Cw3配体结合,由单一转基因抑制性受体进行“教育”。这种方法表明,NK细胞可以被重新编程以在体内控制小鼠同基因肿瘤的发展。此外,体内抗KIR mAb治疗诱导了对HLA(+)靶细胞的杀伤,而没有破坏自身耐受性。最后,长期输注抗KIR mAb既没有消除NK细胞的“教育”,也没有消除肿瘤细胞的识别。因此,这些结果有力地支持了在癌症患者中使用抑制性受体阻断疗法。